2017 Seattle Patient & Survivor Conference
What is Immunotherapy?
Managing Drug Side Effects

From the Pressroom

U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabo…

Continue Reading

FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma

"A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the pot…

Continue Reading

Videos:2017 Kidney Cancer Association Patient & Survivor Conference

Videos from KCA patient and survivor conference that held in North Carolina on December 9th, 2017 is now available onlin…

Continue Reading